Abstracts of Presentations from the 2020 Trans-Agency Scientific Meeting on Developing Medical Countermeasures to Treat the Acute and Chronic Effects of Ocular Chemical Toxicity, 25–26 February, Bethesda, Maryland

Yeung, David T.; Araj, Houmam; McNutt, Patrick

doi:10.1016/j.toxlet.2020.05.026

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Case in point: ocular chemical toxicity—the theme of a recent transagency scientific meeting convened on February 25–26, 2020, in Bethesda, Maryland, by the United States National Institutes of Health (NIH) in partnership with the U.S. Army Medical Research Institute of Chemical Defense. 1 The meeting brought together subject matter experts from the civilian and military research communities to discuss the current state of the field in developing medical countermeasures (MCMs) to treat the acute and chronic effects of ocular chemical toxicity. This perspective highlights some themes that arose at the meeting.…”

Section: Introductionmentioning

confidence: 99%

Ocular Surface – Merging Challenges and Opportunities

Araj

Tumminia

Yeung

2020

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

Dichotomies are double-edged: they can simplify and enlighten as well as exaggerate and entangle. Seeing the eye as anterior segment vs. posterior segment simplifies the formidable task of dissecting the function of the eye. Yet this view creates artificial divisions in a coherent whole. Clearly, vision requires the convergence of the light refractive function of the front of the eye with the light sensing function of the back of the eye. The National Eye Institute has long aimed to foster research across the visual pathway. Finding the right balance is a constant work in progress. A recently held scientific meeting which we co-organized with the United States Army Medical Research Institute of Chemical Defense, offered an opportunity to take stock of what the anterior segment in general, and the ocular surface in particular, bring to our understanding of biology and disease of the eye. Multiple dichotomies surfaced: acute vs. chronic disease; epithelial vs. endothelial damage; fibrotic vs. vascular pathology; inflammation vs. resolution response; chemical exposure vs. countermeasure; monotherapy vs. combination therapy; mechanistic vs. exploratory research; human vs. animal model. Merging some of these dichotomies is the goal of this paper.

show abstract

Section: Introductionmentioning

confidence: 99%

Ocular Surface – Merging Challenges and Opportunities

Araj

Tumminia

Yeung

2020

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fortunately, the ophthalmic research community is ripe with expertise in various aspects and targets of mechanical and nonspecific chemical eye injury as well as acquired and degenerative ocular diseases and disorders that could potentially be recruited to address the currently unmet biosecurity and health preparedness need for effective MCMs. In fact, this was a stated goal of a recent trans-agency scientific meeting convened in February 2020 by the NIH in collaboration with the U.S. Army Medical Research Institute of Chemical Defense of the Department of Defense (Yeung et al, 2020a). Briefly, the meeting offered a venue for basic and applied scientists from academic, industry, and government laboratories with expertise in corneal and retinal injuries, such as alkali burn injuries, ocular complications associated with diabetes, and limbal stem cell deficiency, to identify potentially common pathologies and models that could be utilized to inform therapeutics and MCM development.…”

mentioning

confidence: 99%